Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biogena Group Invest AG's Other Operating Expense for the
six
months ended in Jan. 2026 was €0.17 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2026 was €0.17 Mil.
Biogena Group Invest AG's quarterly Other Operating Expense
increased
from Jan. 2024 (€0.13 Mil) to Jan. 2025 (€0.17 Mil) but then
stayed the same
from Jan. 2025 (€0.17 Mil) to Jan. 2026 (€0.17 Mil).
Biogena Group Invest AG's annual Other Operating Expense
increased
from Jan. 2024 (€0.13 Mil) to Jan. 2025 (€0.17 Mil) but then
stayed the same
from Jan. 2025 (€0.17 Mil) to Jan. 2026 (€0.17 Mil).
Biogena Group Invest AG Other Operating Expense Related Terms
Biogena Group Invest AG Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Biogena Group Invest AG's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogena Group Invest AG Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2026 was €0.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €0.17 Mil mean?
Biogena Group Invest AG (WBO:BIO) has a Other Operating Expense of €0.17 Mil as of Jan. 2026. Other operating expenses that a company records on its income statement. View historical data on Biogena Group Invest AG and its competitors.
Is Biogena Group Invest AG's Other Operating Expense too high?
Biogena Group Invest AG's current Other Operating Expense is €0.17 Mil. Overall, Biogena Group Invest AG has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's Other Operating Expense compare to KHC and GIS?
Biogena Group Invest AG's Other Operating Expense of €0.17 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Consumer Packaged Goods company?
A good Other Operating Expense depends on the Consumer Packaged Goods industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Biogena Group Invest AG and its competitors. Biogena Group Invest AG's current Other Operating Expense is €0.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.52, compared to a current price of €5.35 — trading 52% above its estimated fair value. The current Other Operating Expense is €0.17 Mil. Biogena Group Invest AG's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current Other Operating Expense is €0.17 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued.
The current stock price of €5.35 is trading 52% above its estimated GF Value™ of €3.52.
GuruFocus considers Biogena Group Invest AG to be Significantly Overvalued.
Key valuation signals for WBO:BIO:
Other Operating Expense: €0.17 Mil
GF Value™: €3.52 vs. price of €5.35 (52% above fair value)
No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
62GF Score
Get the complete analysis for WBO:BIO
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BIO has been successfully added to your 
